Introduction: editing disease at its source
Gene editing therapies represent a fundamental shift in how medicine addresses genetic disease. Instead of regulating proteins or pathways downstream of dysfunction, gene editing targets the DNA sequence itself, aiming to produce durable or potentially curative correction. The field has moved rapidly from conceptual biology to clinical translation, guided by new therapeutic modalities such as CRISPR-Cas9, base editing, and prime editing, which differ in precision and mechanism but share a core strategy: modify genetic information directly.
For genetic engineers, the key challenge is now determining which editing approach best aligns with a disease mechanism, cell type, and therapeutic context.
What gene editing therapies do
Gene editing therapies intentionally modify DNA in living cells to correct or disrupt gene function. By working at the genomic level, they can produce long-lasting corrections that continue to propagate through cell division. This is particularly impactful for monogenic diseases, where the biological root cause is singular and clearly defined.
Editing can occur ex vivo, where cells are modified outside the body (as in engineered immune cell therapies), or in vivo, where editing components are delivered directly into tissues. Ex vivo editing offers control and validation before reinfusion; in vivo editing offers direct access to affected tissues but introduces delivery and biodistribution challenges.
CRISPR-Cas9: the first clinically deployed gene editing system
CRISPR-Cas9 uses a guide RNA to direct the Cas9 nuclease to a specific DNA sequence, where it creates a double-strand break (DSB). The cell repairs the break via non-homologous end joining or homology-directed repair, which can disrupt or correct a gene. Its ease of programming and efficiency made CRISPR the first gene editing platform to enter clinical use
(Doudna & Charpentier, Science, 2014).
However, DSBs can introduce:
- Insertions/deletions (indels)
- Chromosomal rearrangements
- On-target but imprecise repair outcomes
These limitations motivated development of editing systems that avoid DNA breaks while retaining targeting precision.
Base editing: correcting single nucleotides without DNA breaks
Base editing enables single-letter DNA changes without generating double-strand breaks. It fuses a catalytically impaired Cas enzyme to a deaminase, producing highly predictable nucleotide conversions.
Base editing has shown particular promise in blood disorders by reactivating fetal hemoglobin production, improving red blood cell function and reducing disease symptoms
(Newby et al., Nature Genetics, 2021).
Because no DSBs occur, genomic stress and rearrangement risk are significantly reduced. Base editing is now central in ex vivo hematopoietic stem cell editing and next-generation T cell engineering efforts.
Prime editing: search-and-replace genome editing
Prime editing expands edit flexibility further by enabling:
- All 12 possible base conversions
- Small insertions and deletions
- Sequence rewriting without donor templates
Prime editors fuse a Cas9 nickase to a reverse transcriptase, guided by a prime editing guide RNA (pegRNA) that encodes the desired edit. This architecture allows targeted DNA rewriting with fewer unintended edits
(Anzalone et al., Nature, 2019).
While efficiency varies by cell type, prime editing is currently one of the most versatile precision editing platforms under development.
Delivery: the central bottleneck
Despite advances in editing chemistry, therapeutic success depends on whether editors can reach the right cells.
- AAV vectors are effective for eye, muscle, and liver delivery but have cargo limits and immune risk
(Mendell et al., NEJM, 2017). - Lipid nanoparticles (LNPs), widely adopted in mRNA vaccines, offer transient expression and liver tropism, and are rapidly being adapted for other tissues
(Hassett et al., Molecular Therapy, 2019). - Ex vivo electroporation remains the standard for CAR-T and stem cell editing, providing controlled delivery but limiting in vivo applicability.
The next generation of editing therapies will depend heavily on delivery vector engineering rather than editing chemistry alone.
Future outlook: curative and programmable medicine
The field is now progressing toward:
- In vivo editing for systemic genetic diseases
- Transient, non-viral delivery to minimize immunogenicity
- Cell-type-specific targeting ligands
- Editing systems that are reversible, inducible, or self-limiting
- Integration with cell therapy, mRNA therapy, and epigenetic modulation
As precision increases and delivery barriers are reduced, gene editing is expected to expand beyond rare diseases into immunology, neurology, and regenerative medicine, shifting medicine toward repair instead of compensation.
Conclusion
Gene editing therapies represent a new treatment paradigm: address disease at its cause, not its consequences. CRISPR established feasibility; base editors improved precision; prime editors expanded capability. Together, they form a modular toolkit for durable, targeted genomic repair.
The future of therapeutics increasingly depends not on finding the right drug —
but on writing the correct genetic instructions.
Frequently Asked Questions (FAQ)
1. How are gene editing therapies different from traditional gene therapy?
Traditional gene therapy introduces a functional gene copy, but does not correct the underlying mutation. Gene editing therapies modify the existing genomic sequence, enabling durable correction and normal gene regulation.
2. Why is delivery the key challenge in gene editing?
Editing tools must reach the right cells and remain active long enough to produce the desired change. Achieving cell-specific uptake while avoiding immune activation or off-target editing remains the central bottleneck in in vivo gene editing.
3. When is base editing preferred over CRISPR-Cas9?
Base editing is favored when the therapeutic goal is a precise single-nucleotide correction and when avoiding double-strand breaks is important, such as in hematopoietic stem cells and engineered T cell programs.
4. Where does prime editing fit into future clinical development?
Prime editing offers the most flexible rewriting capabilities, allowing insertions, deletions, and all base conversions without DSBs. It is still undergoing optimization but is viewed as the platform most likely to generalize repair across diverse genetic diseases.
References
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.
Newby GA, Yen JS, Woodard KJ, et al. Base editing in human hematopoietic stem cells for hemoglobinopathy correction. Nature Genetics. 2021;53(4):515–525.
Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks. Nature. 2019;576(7785):149–157.
Mendell JR, Al-Zaidy SA, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. New England Journal of Medicine. 2017;377(18):1713–1722.
Hassett KJ, Benenato KE, Jacquinet E, et al. Optimization of lipid nanoparticles for mRNA delivery. Molecular Therapy. 2019;27(12):2175–2188.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
